Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Ewing 2Sarcoma, Clear Cell 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Sarcoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Fibroma 1

Interventions

Cyclophosphamide 10Doxorubicin 9Vincristine 7Etoposide 7Ifosfamide 6Filgrastim 5Radiotherapy 4fludarabine phosphate 3Topotecan 3Thiotepa 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Cisplatin 3Carboplatin 3Brachytherapy 3seclidemstat 2Tacrolimus 2PM 01183 2Neoadjuvant Therapy 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Granulocyte Colony-Stimulating Factor 2Epirubicin 2Dactinomycin 2Cytoreduction Surgical Procedures 2Cyclosporine 2Chemotherapy, Adjuvant 2thymoglobulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Desmoplastic Small Round Cell Tumor × seclidemstat × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡